Submitted:
26 September 2024
Posted:
27 September 2024
You are already at the latest version
Abstract
Keywords:
1. Clinical Data
1.1. Study Population
1.2. Diagnostic Criteria
1.3. Inclusion Criteria
1.4. Exclusion Criteria
1.5. Exclusion and Dropout Criteria Exclusion Criteria
2. Research Methods
2.1. Treatment Methods
2.2. Observation Indicators
2.3. Statistical Analysis
Results
3.1. Patient Completion Status
3.2. Baseline Characteristics
3.3. AFEQT Scale Score
3.4. AF Recurrence 3 Months after CA
3.5. Adverse Events
4. Discussion
References
- Hindricks G, Potpara T, Dagres N,et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC[J]. European Heart Journal, 2021, 42(5): 373–498.
- Baman J R, Passman R S. Atrial fibrillation[J]. Nat Rev Dis Primers, 2022, 8(1): 20.
- Baman J R, Passman R S. Atrial fibrillation[J]. JAMA, 2021, 325(21): 2218.
- Chugh S S, Havmoeller R, Narayanan K,et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study[J]. Circulation, 2014, 129(8): 837-847.
- Schnabel R B, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study[J]. Lancet, 2015, 386(9989): 154–162.
- Greccia D, Manicardi M, Malavasi V L, et al. Comparing outcomes in asymptomatic and symptomatic atrial fibrillation: a systematic review and meta-analysis of 81,462 patients[J]. J Clin Med, 2021, 10(17): 3979. [CrossRef]
- Chugh S S, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study[J]. Circulation, 2014, 129(8): 837-847.
- Chinese Association of Rehabilitation Medicine Cardiovascular Disease Prevention and Rehabilitation Professional Committee. Chinese expert consensus on cardiac rehabilitation for patients with atrial fibrillation [J]. Chinese Journal of Internal Medicine, 2021, 60(2): 106-116.
- Zhang Rui, Wei Ling Bo. Clinical research progress of traditional Chinese medicine in the treatment of AF[J]. Journal of Integrated Traditional Chinese and Western Medicine for Cardiovascular and Cerebrovascular Diseases, 2019, 17(19): 2962-2964.
- Huang Xinmiao, Qu Xiufen. Atrial fibrillation and autonomic nervous system Research progress on the correlation of [J]. Chinese Journal of Circulation, 2015, 30(10): 1027-1029.
- Liu Cunzhi. Evidence-based medical evidence and future design ideas for acupuncture treatment of cardiovascular diseases [J]. Chinese Traditional and Western Medicine Integrated Journal, 2019, 39(11): 1306-1308.
- Zhang Rui, Wei Lingbo. Clinical research progress of traditional Chinese medicine in the treatment of atrial fibrillation [J]. Journal of Integrated Traditional Chinese and Western Medicine for Cardio-Cerebral Vascular Disease, 2019, 17( 19): 2962-2964.
- Zhang Yonghuan, Zhou Shenghong. Research progress on acupuncture combined with drugs in the treatment of atrial fibrillation [J]. Clinical Research in Traditional Chinese Medicine, 2017, 9(10): 131-133.
- Zhao Weidong, Tan Wei , Yi Guangqiang et al. Clinical study on the treatment of sinus bradycardia with heart and spleen deficiency syndrome after modified maze surgery by Wenyang Tongmai acupuncture [J]. Clinical Journal of Acupuncture and Moxibustion, 2015, 31(4): 31-33.
- Analysis of the use of placebo acupuncture in domestic randomized controlled trials in the past five years by Wang Shouyan, Wang Hui, Cai Fei and others [J]. Shanghai Journal of Acupuncture, 2017, 36(10): 1269-1276.
- Wang Yuhai. Micro-needle knife treatment of the elderly Clinical observation of 27 cases of human idiopathic atrial fibrillation [J]. Huaihai Medicine, 2007, 25(2): 142.
- Chen Li, Chen Zhifang, Yang Xiaoxue, etc. Effectiveness of Neiguan acupoint catgut embedding in the treatment of atrial fibrillation and safety [J]. New Traditional Chinese Medicine, 2012, 44(8): 148-150.
- Ren Jie. Comparing the effects of different acupuncture depths of Neiguan points on atrial fibrillation electrocardiogram and atrial structure in rats with atrial fibrillation [D ]. Beijing: Beijing University of Chinese Medicine, 2019.
- Wang Huan, Cheng Kai, Ren Jie, et al. Effects of acupuncture pretreatment at "Jiquan" and "Neiguan" points on atrial fibrillation duration and Cx40 protein in rats with atrial fibrillation and the influence of mRNA expression[J]. Clinical Journal of Acupuncture and Moxibustion, 2019, 25(6): 74-78.
- Mark D. Assessing quality-of-life outcomes in cardiovascular clinical research [J]. Nat Rev Cardiol, 2016, 13(5): 286-308.
- Freeman J, Simon D, Go A, et al. Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) [J]. Circ Cardiovasc Qual, 2015, 8(4): 393-402.
- Li Yingyi, Wang Qunshan. Quality of life assessment and latest symptom classification method for patients with atrial fibrillation [J]. Chinese Journal of Circulation, 2015, 30(7): 3.
- Zhou He, Xu Yawei. Evaluation of intelligent electrocardiogram detectors Accuracy of diagnosing arrhythmias[J]. Beijing Biomedical Engineering, 2022, 41(1): 73-78.

| Item | Acupuncture group (n=35 ) | Sham Acupuncture group (n=35) | χ2/Z/t value | P value |
|---|---|---|---|---|
| Clinical characteristic | ||||
| Age, y | 69.3±5.2 | 67.5±6.1 | 0.17 | 0.89 |
| Male, n (%) | 21(60.00) | 21(60.00) | 0.00 | 1.00 |
| BMI, kg/m2 | 25.4±2.4 | 24.9±2.5 | 1.23 | 0.51 |
| Type of atrial fibrillation,n (%) | 0.12 | 0.98 | ||
| Paroxysmal AF | 31(88.57) | 30(85.71) | ||
| Persistent AF | 4(11.43) | 5(14.29) | ||
| AF duration (months) | 10.6±9,9 | 12.1±11.2 | 1.01 | 0.43 |
| Echocardiographic data | ||||
| LAD (mm,x̅±s) | 41.1±6.7 | 42.9±5.6 | 1.32 | 0.31 |
| LVEF(%,x̅±s) | 56.9±4.2 | 55.8±4.4 | 0.07 | 0.79 |
| CHA2DS2-VASc score | 2.1±1.1 | 1.9±1.5 | 0.21 | 0.89 |
| HAS-BLED score | 1.1±1.2 | 0.9±1.1 | 0.19 | 0.88 |
| Classification of cardiac function,n (%) | 0.05 | 0.91 | ||
| I | 21(60.00) | 22(62.86) | ||
| II | 14(40.00) | 13(37.14) | ||
| Comorbidities,n(%) | ||||
| hypertension | 19(54.29) | 19(54.29) | 0.00 | 1.00 |
| coronary artery disease | 12(34.29) | 13(37.14) | 0.10 | 0.95 |
| diabetes | 16(45.71) | 14(40.00) | 0.18 | 0.87 |
| Stroke | 8(22.86) | 7(20.00) | 0.10 | 0.95 |
| Hyperlipidemia | 7(20.00) | 7(20.00) | 0.00 | 1.00 |
| Other arrhythmias | 3(8.57) | 4(11.43) | 0.11 | 0.94 |
| Ablation procedure | ||||
| PVI, n (%) | 35(100) | 35(100) | 0.00 | 1.00 |
| CTI, n (%) | 3(8.57) | 4(11.43) | 0.11 | 0.94 |
| Roof line, n (%) | 5(14.29) | 5(14.29) | 0.00 | 1.00 |
| Perimitral line, n (%) | 2(5.71) | 2(5.71) | 0.00 | 1.00 |
| ECV, n (%) | 5(14.29) | 6(17.14) | 0.10 | 0.97 |
| Drugs use | ||||
| Aspirin, n (%) | 5(14.29) | 3(8.57) | 0.17 | 0.89 |
| Warfarin, n (%) | 2(5.71) | 2(5.71) | 0.00 | 1.00 |
| NOAC, n (%) | 30(85.71) | 31(88.57) | 0.12 | 0.98 |
| Beta-blockers, n (%) | 25(71.43) | 23(65.71) | 0.10 | 0.95 |
| ACEI/ARB, n (%) | 15(42.86) | 16(45.71) | 0.11 | 0.96 |
| Statins, n (%) | 21(60.00) | 19(54.29) | 0.00 | 0.99 |
| CCB, n (%) | 11(31.43) | 12(34.29) | 0.10 | 0.98 |
| Diuretic, n (%) | 9(25.71) | 11(31.43) | 0.12 | 0.96 |
| OHA, n (%) | 16(45.71) | 14(40.00) | 0.10 | 0.97 |
| Item | Acupuncture group (n= 30) | t value |
P value | Sham Acupuncture group (n=29) | t value |
P value | ||
|---|---|---|---|---|---|---|---|---|
| Before treatment | Treatment for 3 months | Before treatment | Treatment for 3 months | |||||
| Total score (x̅±s) | 58.33±25.21 | 82.35±25.31 | 4.38 | <0.01 | 61.41±25.81 | 80.55±23.12 | 3.95 | 0.01 |
| Symptoms (x̅±s) | 61.54±20.98 | 85.66±19.43 | 3.15 | <0.01 | 59.01±24.30 | 81.49±26.09 | 3.03 | <0.01 |
| Daily activities (x̅±s) | 59.98±29.54 | 78.70±20.77 | 4.81 | <0.01 | 59.55±31.41 | 72.54±19.87* | 2.98 | <0.01 |
| Treatment worry (x̅±s) | 61.44±21.09 | 89.79±18.35 | 4.01 | <0.01 | 62.45±29.01 | 75.19±21.31* | 2.89 | <0.01 |
| AF control | 51.90±29.71 | 79.01±30.91 | 3.51 | <0.01 | 50.43±23.11 | 76.37±24.54 | 3.41 | <0.01 |
| Symptoms | 49.91±18.34 | 84.31±21.33 | 4.59 | <0.01 | 51.10±21.91 | 75.01±28.60* | 2.99 | 0.01 |
| Item | Acupuncture group (n=30 ) | Sham Acupuncture group (n=29) | χ2/t value | P value |
|---|---|---|---|---|
| AF load(%) | 0.00 | 0.00 | 0.58 | 0.89 |
| Recurrence of AF, n (%) | 3(10.00) | 5(17.24) | 0.01 | 0.98 |
| The number of hospitalization due to arrhythmia, n (%) | 3(10.00) | 4(13.79) | 0.01 | 0.98 |
| Item | Acupuncture group (n=30) | Sham Acupuncture group (n=29) | χ2value | P value |
|---|---|---|---|---|
| Haemorrhage or hematoma | 1(3.30) | 2(6.90) | 0.00 | 1.00 |
| Other adverse reactions | 0(0.00) | 0(0.00) | 0.00 | 1.00 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).